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Dissociation between morphine-induced spinal gliosis and
analgesic tolerance by ultra-low-dose α2-adrenergic and
cannabinoid CB1-receptor antagonists
Patrick Greniera, David Wiercigrochb, Mary C. Olmsteadb and
Catherine M. Cahilla,c
Long-term use of opioid analgesics is limited by tolerance
development and undesirable adverse effects.
Paradoxically, spinal administration of ultra-low-dose (ULD)
G-protein-coupled receptor antagonists attenuates
analgesic tolerance. Here, we determined whether systemic
ULD α2-adrenergic receptor (AR) antagonists attenuate the
development of morphine tolerance, whether these effects
extend to the cannabinoid (CB1) receptor system, and if
behavioral effects are reflected in changes in opioid-
induced spinal gliosis. Male rats were treated daily with
morphine (5mg/kg) alone or in combination with ULD α2-
AR (atipamezole or efaroxan; 17 ng/kg) or CB1 (rimonabant;
5 ng/kg) antagonists; control groups received ULD
injections only. Thermal tail flick latencies were assessed
across 7 days, before and 30min after the injection. On day
8, spinal cords were isolated, and changes in spinal gliosis
were assessed through fluorescent immunohistochemistry.
Both ULD α2-AR antagonists attenuated morphine
tolerance, whereas the ULD CB1 antagonist did not. In
contrast, both ULD atipamezole and ULD rimonabant
attenuated morphine-induced microglial reactivity and
astrogliosis in deep and superficial spinal dorsal horn.
So, although paradoxical effects of ULD antagonists are
common to several G-protein-coupled receptor systems,
these may not involve similar mechanisms. Spinal glia alone
may not be the main mechanism through which tolerance is
modulated. Behavioural Pharmacology 29:241–254
Copyright © 2018 Wolters Kluwer Health, Inc. All rights
reserved.
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Introduction
Opioids are highly efficacious in the treatment of moderate
to severe acute postoperative and traumatic injury-induced
pain. The therapeutic usefulness of these drugs in the
treatment of many long-term and persistent pain states is
limited by a decrease in efficacy (Ballantyne and Shin, 2008)
and potency (Christie, 2008), as well as the development of
opioid-induced hyperalgesia (Mao, 2002). One novel strategy
to mitigate analgesic tolerance is through concomitant use of
ultra-low-dose (ULD) G-protein-coupled receptor (GPCR)
antagonists. ULD is defined as a concentration several log
units below the levels that result in ligand-induced receptor
activity. Preclinical studies have shown that long-term
administration of ULD opioid antagonists, such as nalox-
one and naltrexone, does not inhibit opioid-induced phar-
macological effects, but rather enhances the antinociceptive
effects of morphine (Tsai et al., 2008), suppresses the
development of opioid analgesic tolerance (Shen and Crain,
1997; Powell et al., 2002; Terner et al., 2006; McNaull et al.,
2007; Tuerke et al., 2011), and reduces opioid withdrawal
symptoms (Mannelli et al., 2004; Olmstead and Burns, 2005).
This phenomenon has also been observed clinically, where
ULD naltrexone enhances and prolongs oxycodone analge-
sia in patients experiencing osteoarthritis (Chindalore et al.,
2005) and reduces physical dependence compared with
oxycodone alone in patients with long-term low back pain
(Webster et al., 2006).
This ULD phenomenon is not restricted to opioid receptor
antagonists. Recent studies demonstrated that long-term
intrathecal administration of an ULD α2-adrenergic receptor
(AR) antagonist, atipamezole, enhances clonidine analgesia
in rats (Milne et al., 2011). In addition, structurally diverse
α2-AR antagonists, including efaroxan (Milne et al., 2013)
and the α2A-AR subtype selective BRL44408 (Milne et al.,
2014), are able to augment spinal morphine analgesia and
attenuate development of short-term and long-term opioid
tolerance (Milne et al., 2008).
Given the close connections between opioid and canna-
binoid (CB) systems, it is not surprising that ULD effects
on analgesic tolerance extend to the CB receptor system.
Opioid and CB receptor systems cross-modulate activity
(Robledo et al., 2008), are colocalized in spinal (Salio et al.,
2001) and supraspinal regions, and have similar signal
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transduction pathways; both are coupled to inhibitory
G-protein pathways (Rodriguez et al., 2001) and mediate
analgesia by inhibiting release of pronociceptive neuro-
chemicals. Short-term activation of either receptor type
leads to analgesia, antinociceptive synergy is observed
when both are activated (Cichewicz, 2004), and repeated
stimulation leads to analgesic tolerance and receptor
desensitization (Dewey, 1986; Olson et al., 1998). ULD
opioid antagonists attenuate the development of toler-
ance to (Paquette et al., 2007) and enhance the anti-
nociceptive effects of (Paquette and Olmstead, 2005)
CB1-receptor agonists. One goal of this study was to test
the inverse relationship: whether ULD CB antagonists
alter the development of tolerance to opioid agonists.
Although the paradoxical effect of ULD antagonists is more
ubiquitous than once believed, the mechanism through
which this occurs is not understood. One possibility is that
modulation of spinal gliosis plays a role in ULD effects on
analgesic tolerance. Repeated morphine administration leads
to glial activation in the brain and spinal cord (Raghavendra
et al., 2002), causing a shift to a proinflammatory state
(Watkins and Maier, 2004; Hutchinson et al., 2007; Jo et al.,
2009). Importantly, pharmacological inhibition of glia
attenuates the development of morphine tolerance (Song
and Zhao, 2001; Mika et al., 2009). Long-term coadminis-
tration of the ULD opioid antagonist, naltrexone, attenuates
the development of morphine-induced spinal gliosis and
opioid analgesic tolerance (Mattioli et al., 2010). Because of
similarities across receptor systems, we hypothesized that
comparable effects would be observed with other GPCRs
displaying paradoxical ULD antagonist activity, including
the α2-adrenergic and CB1-receptor antagonists.
This study aimed to determine whether systemic adminis-
tration of ULD α2-AR antagonists enhances morphine
analgesia and whether the mechanism of action was at least
partially mediated through modulation of spinal glia. Thus,
we investigated the long-term systemic effects of two che-
mically distinct ULD α2-AR antagonists, atipamezole and
efaroxan, and an ULD CB1-receptor antagonist, rimonabant
(RIM), on (i) the development of long-term morphine
tolerance and (ii) morphine-induced spinal gliosis. To assess
the latter, we used fluorescent immunohistochemistry
and three-dimensional cellular reconstructions to quantify
expression of CD11b and glial fibrillary acidic protein
(GFAP), proteins that upregulate in activated microglia and
astrocytes, respectively. This allowed us to assess changes in
glial cell size associated with a proinflammatory phenotype
that drives changes in receptor function and cell signaling
pathways leading to the development of tolerance.
Methods
Subjects
Male Sprague-Dawley rats (Charles River Laboratories,
Montreal, Quebec, Canada) weighing 250–300 g were
used for all experiments. Animals were pair-housed, kept
on a reverse 12-h/12-h light/dark cycle with lights off at
07 : 00 h, and provided with free access to food and water
in their home cage. Upon arrival, animals were allowed to
habituate to their new surroundings for 3 days before
handling and at least 7 days before the start of experi-
mentation. All behavioral testing was performed blind to
treatment during the animals’ active phase, before
14 : 00 h. Animals were randomly assigned to treatment
groups, and both animals within a cage received the same
treatment.
All experiments were performed in accordance with
guidelines set by the Canadian Council on Animal Care
and were approved by the Queen’s University Animal
Care Committee. Care was taken to minimize the num-
ber of animals needed for behavioral experiments that
would still provide a robust enough effect to show sta-
tistical differences between treatment groups, if any.
Although the nature of the study relies on exposure to a
painful stimulus to assess changes in the antinociceptive
effects of drugs over time, safety measures included the
following: cutoff times to avoid tissue damage built into
the experimental design to minimize distress, animals
were only subjected to one test session per day, exposure
to the nociceptive stimulus was terminated as soon as the
rats withdrew from it, and the duration of the experi-
ments was kept as short as possible while still allowing for
robust development of opioid analgesic tolerance.
Although perfusion for tissue collection needs to be done
on live animals with a beating heart, the animals were
deeply anesthetized during the procedure. To ade-
quately model pain and reflex pathways, the species
must be of sufficient complexity and exhibit structural
and behavioral similarities to humans. Rats are a well-
validated model for studies of this nature, and use of
species lower on the phylogenetic tree would not provide
useful behavioral data.
Thermal tail flick assay
The 5-cm distal portion of the rat tail was marked with a
permanent black marker, and a thermal tail flick
analgesiometer (IITC Life Science Inc., Woodland Hills,
California, USA) was used to determine tail flick laten-
cies, as described previously (D’Amour and Smith, 1941).
Baseline thresholds were assessed before the start of each
experiment on the same day, with the beam intensity
adjusted to elicit tail flick latencies between 2 and 3 s,
then kept constant throughout all trials. A cutoff was set
at three times baseline (8 s) to avoid tissue damage.
Tolerance paradigm
Animals were randomly assigned to one of four groups:
morphine (5mg/kg, subcutaneous), morphine and ULD
atipamezole (17 ng/kg, subcutaneous), ULD atipamezole
alone (17 ng/kg, subcutaneous), or vehicle (0.9% saline,
0.1ml/100 g, subcutaneous). Thermal tail flick latencies
were assessed daily before and following drug injections (at
30min, corresponding to analgesic peak effects produced by
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morphine alone) for 7 days. Two-hour time courses were
performed on the first and seventh day to compare changes
in analgesic response profiles at the beginning and the end
of the trial. This protocol was used to assess the effects of
coadministration of ULD efaroxan (17 ng/kg, subcutaneous)
compared with morphine alone in separate groups of ani-
mals. A third experiment was conducted in separate groups
of animals to assess the effect of coadministration of ULD
CB1-receptor antagonist RIM (1, 5, 50 ng/kg) with morphine
compared with morphine alone (5mg/kg) or vehicle [5%
dimethylsulfoxide (DMSO), 0.3% Tween-80 in 0.9% saline]
over 7 days. Our previous studies reported that ULD α2-
adrenergic antagonists, atipamezole and efaroxan (Milne
et al., 2008, 2013, 2014), or CB1-antagonist RIM (Paquette
et al., 2007) do not alter nociceptive thresholds, and
therefore to minimize use of animals, these control groups
were not repeated in all experiments.
Sacrifice, perfusion, and tissue isolation
On the eighth day, 24 h after the last drug treatment, rats were
deeply anesthetized with sodium pentobarbital (75mg/kg,
intraperitoneal; MTC Pharmaceuticals, Cambridge, Ontario,
Canada) and perfused transaortically with 500ml of cold 4%
paraformaldehyde in 0.1mol/l PBS. Rats were decapitated,
and spinal cords were ejected and postfixed in ice-cold 4%
paraformaldehyde for 30min. Spinal cords were then cryo-
protected by immersion in 30% sucrose (dissolved in 0.1mol/l
PBS) at 4°C for 48–72 h, and then snap-frozen in −45°C
isopentane over dry ice and placed in a −80°C freezer for
storage until the start of immunohistochemical labeling.
Immunohistochemistry
To assess whether the ULD α2-adrenergic and CB1-
receptor antagonists modified spinal gliosis associated with
tolerance from prolonged morphine treatment, immuno-
histochemistry was performed on lumbar spinal cord tissue
to label and quantify markers expressed on astrocytes and
microglia, GFAP and CD11b, respectively.
L4–L5 lumbar spinal cord sections were cut transversely
(30 µm) using a freezing sledge microtome and collected
in 0.1 mol/l Tris-buffered saline (TBS). Sections were
washed 1× 5 min in 0.1 mol/l TBS, and then 1× 5 min in
0.1M TBS-Triton (TBS-T) to increase antibody pene-
tration. Tissue was blocked for 2 h at room temperature
with blocking buffer containing 10% normal goat serum
(NGS) and 10% BSA in 0.1 mol/l TBS-T to reduce the
likelihood of nonspecific labeling.
Sections were incubated with primary antibody solution
containing 1% NGS and 1% BSA in 0.1 mol/l TBS-T
overnight at 4°C to label microglia (anti-CD11b, raised in
mouse, 1 : 1000 dilution, MLA257R, batch: 0404; anti-
CD68, raised in mouse, 1:250 dilution, MCA341, AbD
Serotec, Raleigh, North Carolina, USA) or astrocytes
(anti-GFAP, raised in rabbit, 1 : 2500 dilution, Z0334, lot:
00045904; Dako, Glostrup, Denmark). Microglia and
astrocyte labeling was performed on separate tissue
sections.
Sections were then washed at room temperature
2× 5min, and then 2× 10 min in 0.1 mol/l TBS-T before
incubation at room temperature for 2 h (in the dark) with
appropriate secondary antibodies conjugated to Alexa
fluorophores (Thermo Fisher Scientific, Waltham,
Massachusetts, USA) at 1 : 200 dilution in 5% NGS and
5% BSA in 0.1 mol/l TBS-T. GFAP-labeled tissue was
incubated with a 488-nm anti-rabbit secondary, whereas
the CD11b-labeled tissue sections were incubated with a
594-nm anti-mouse secondary. After incubation, sections
were washed 3× 10 min in 0.1 mol/l TBS-T, and then
1× 10min in 0.1 mol/l TBS before mounting on glass
microscope slides in 0.1 mol/l TB, air-dried and cover-
slipped with Aquamount (Polysciences Inc., Warrington,
Pennsylvania, USA). Slides were stored in the dark in the
fridge at 4°C until imaging with a confocal microscope.
Confocal imaging
Imaging of CD11b and GFAP fluorescent labeling was
performed on a confocal microscope (Leica TCS SP2
Multi Photon Laser Scanning confocal microscope; Leico
Microsystems, Wetzlar, Germany). Images were captured,
blind to treatment, within the deep dorsal horn (in lamina
V) and the superficial dorsal horn (within laminae I,II).
Images were captured in stacks through the z-plane (to
allow for later three-dimensional reconstruction) at × 63
magnification under oil immersion. Settings such as gain
and the number of passes (to clean up background noise)
were optimized for each fluorophore at the beginning of
the imaging and kept constant across all treatment groups
for the entire duration, allowing comparison of fluorescent
intensity across different animals and treatments.
Quantification of fluorescent labeling intensity
For quantification of average pixel intensity in two-
dimensional images, all the layers of each three-dimensional
stack were collapsed using ImageJ software (U.S. National
Institutes of Health, Bethesda, Maryland, USA) by using its
Z Project function (with Maximum Intensity set as the
Projection Type). Collapsed images were ‘measured’ in
ImageJ, and the mean pixel intensities were compared across
treatment groups. Overall, three to six sections were imaged
per animal in each area (deep and superficial dorsal horn)
from at least three animals per group.
Three-dimensional reconstructions and assessment of
cell size
Mean pixel intensity in a two-dimensional image gives a
good assessment of the density of the cells in the image but
does not provide information about cell size: another metric
of gliosis. Thus, to compare cell size of astrocytes, three-
dimensional reconstructions of the collected GFAP-labeled
stacks were performed using ImagePro Plus 6.0 software
(Media Cybernetics, Rockville, Maryland, USA). Stacks
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were imported into ImagePro Plus, and Merge Images was
used to create a video representation of the stack. Using the
3D Constructor, voxel and subsampling size was set at x=4,
y=4, z= 1 pixels and kept constant throughout. Global
Transparency and Surface Value settings were optimized
with the first stack and kept constant for all other stacks. No
filters were used for volume measurements. Close edges
was used, and Isosurface Simplification was set to medium
as this gave the best and most consistent assessment of
individual cells. The volume of all cells was determined
throughout the entire stack. Cell volumes were sorted from
largest to smallest, and the volumes of the three largest cells
were recorded for each stack. The stacks were not adjusted
or manipulated in any way, and the volumes were recorded
exactly as the software detected them, with all settings kept
constant. A total of four to six stacks were reconstructed in
each area (deep and superficial dorsal horn) per animal from
at least three animals per group.
Drug administration
All drugs were administered through once daily sub-
cutaneous injection. For the ULD α2-adrenergic antagonist
studies, atipamezole hydrochloride (17 ng/kg; Orion Pharma,
Esposo, Finland), efaroxan hydrochloride (17 ng/kg; Tocris
Bioscience, Ellisville, Mississippi, USA), and morphine
sulfate (MS, 5mg/kg; Sandoz Canada Inc., Boucherville,
Quebec, Canada) were dissolved in 0.9% sterile saline. The
dose was selected on the basis of pilot studies. For the ULD
CB1-receptor antagonist study, MS (5mg/kg) and ULD
RIM (5 ng/kg) were dissolved in vehicle of 5% DMSO
(Thermo Fisher Scientific) in 0.9% saline as used in pre-
vious experiments (Paquette et al., 2007) owing to the poor
solubility of the CB antagonist in aqueous solution.
Because two different vehicles were used for the adre-
nergic and CB antagonists, more than one vehicle behavior
group was included.
Data analysis
Behavioral responses were analyzed by two-way or three-
way analysis of variance (ANOVA) using GraphPad Prism
7.0 software (GraphPad Software Inc., La Jolla,
California, USA) with time as a within-subjects factor and
morphine or ULD antagonist as between-subjects fac-
tors. P value less than 0.05 was considered statistically
significant, and Bonferroni’s or Tukey’s post-hoc analysis
was performed for multiple comparisons. Data are
expressed as mean ± SEM. All data collected were
included in the data analysis, and no data were omitted.
The hypothesis tested was considered two tailed.
Statistical analyses for immunohistochemical experiments
comparing mean pixel intensity of spinal CD11b and
GFAP labeling and astrocyte hypertrophy were performed
using two-way ANOVA with Tukey’s post-hoc analysis.
All GFAP cell volume measurements and 2D immunor-
eactivity in the ULD RIM experiment were analyzed by
nonparametric two-tailed Mann–Whitney U-test.
Results
Analgesic tolerance
Long-term daily administration of morphine (5mg/kg, sub-
cutaneous, for 7 days) significantly reduced the ability of
morphine to elicit thermal antinociception (Fig. 1a), as evi-
denced by a decrease in tail flick latencies measured 30min
after daily morphine injections (at peak effect). Concomitant
administration of either ULD α2-adrenergic antagonist (ati-
pamezole or efaroxan) with morphine significantly attenuated
the development of analgesic tolerance (Fig. 1a and b, left).
Statistical analyses by two-way or three-way ANOVAs are
presented in Table 1. Post-hoc analysis revealed a significant
effect at day 4 in the atipamezole experiment and days 4–6 in
the efaroxan experiment compared with animals receiving
morphine alone. Long-term systemic administration of ULD
atipamezole alone or saline vehicle did not change thermal
withdrawal latencies over 7 days (Fig. 1a, left).
A 2-h time course of morphine or morphine+ α2-adre-
nergic antagonist was determined on days 1 and 7. On
day 1, there was no difference in thermal tail flick
latencies between animals receiving morphine and those
receiving morphine coadministered with ULD atipame-
zole (17 ng/kg) (Fig. 1a, middle) or with ULD efaroxan
(Fig. 1b, middle). For the atipamezole experiment, sta-
tistical analysis of the 2-h time course on day 7 revealed
significant effects of morphine, atipamezole, and mor-
phine× atipamezole (Table 1). Post-hoc analysis revealed
no significant difference between the morphine and the
morphine+ atipamezole groups. However, a two-way
ANOVA of morphine and morphine+ atipamezole groups
revealed a significant effect of treatment [F(1,42)=19.03,
P<0.001] but no difference was identified at any specific
time point. For the efaroxan experiment, two-way ANOVA
of the 2-h time course on day 7 for the morphine and
morphine+efaroxan groups revealed significant effects of
treatment and time (Table 1). Animals that had been
treated with morphine showed tail flick latencies not sig-
nificantly different from their baseline responses before any
drug treatment, whereas the animals that had been
chronically treated with morphine+ efaroxan (Fig. 1b, right)
had significantly higher tail flick latencies compared with
the morphine only groups at 15–60min after injection.
To determine whether short-term synergistic or additive
effects exist between morphine and ULD atipamezole
that would not be detected at maximal analgesic doses of
morphine, we coadministered ULD atipamezole with
submaximal doses of morphine. No additive effects of
the combination were evident (data not shown), sug-
gesting that any potential additive or synergistic effects
do not account for the ability of ULD atipamezole to
attenuate the development of tolerance.
Over the 2-h time course following the first injection,
both morphine alone and morphine+ULD RIM (5 ng/kg)
significantly increased tail flick latencies over the entire 2 h,
compared with vehicle at all time points (Fig. 1c). However,
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there was no significant effect of treatment, indicating that
RIM had no effect on the development of morphine
analgesic tolerance (see Table 1 for statistical analyses). A
two-way ANOVA of day 1 of morphine and morphine+
RIM revealed no significant difference between groups:
tail flick latencies of animals treated with morphine alone
did no differ significantly over the 2 h of testing from those
treated with morphine+ULD RIM (Fig. 1c, middle). By
day 7, however, the antinociceptive effects of morphine
were absent, and coadministration of RIM with morphine
had no effect on the development of analgesic tolerance
(see Table 1 for statistics). Two other doses of ULD RIM
were also assessed (1 ng/kg, 50 ng/kg), but neither of those
two doses had any effect on morphine antinociception or
tolerance development either (data not shown).
Effects of ultra-low-dose antagonists on morphine-
induced gliosis
To quantify changes in microglial and astrocyte activation,
CD11b and GFAP were labeled correspondingly through
fluorescent immunohistochemistry, and stacks were cap-
tured on a confocal microscope within the deep and super-
ficial dorsal horn of the spinal cord, in animals treated for 7
consecutive days with morphine (5mg/kg), morphine+
ULD atipamezole (17 ng/kg), ULD atipamezole alone
(17 ng/kg), or saline (vehicle). In separate groups of animals,
morphine, morphine+ULD RIM, or vehicle (5% DMSO,
0.3%Tween-80 in saline) were also assessed. Representative
micrographs of microglial (CD11b) and astrocyte (GFAP) cell
surface markers are presented (Fig. 2). As previously repor-
ted, morphine significantly increased expression of microglial
protein expression, indicative of opioid-induced neuroin-
flammation. This was evident in both the superficial
(Fig. 3b) and deep (Fig. 3a) dorsal horn of the spinal cord
(see Table 2 for statistics). Post-hoc analyses revealed a
significant difference between saline and morphine in
vehicle-treated groups in the deep (P<0.01) and superficial
spinal cord (P<0.001). However, there was no significant
difference between saline and morphine treatment in the
atipamezole-treated groups in either the superficial or deep
Fig. 1
Long-term coadministration of ULD α2-adrenergic receptor antagonists Ati or Efx, but not ULD CB1-receptor antagonist RIM, attenuates the
development of MS tolerance. Left: thermal tail flick latencies at 30min after injection (peak effect) across 6 days of testing. Middle: 2-h time course
following the first injection. Right: 2-h time courses following the final injection on day 7. MS was administered with ULD Ati (a), ULD Efx (b), or ULD RIM (c).
The lower dotted boundary lines indicate mean baselines before the start of the trial within each cohort. The upper dotted boundary lines indicate the cutoff.
Data displayed as mean±SEM. Group sizes: n=4–5 per group for the ULD atipamezole and efaroxan studies; n=8/group for the ULD RIM study.
Significant difference *P<0.05, compared with MS. Ati, atipamezole; Efx, efaroxan; MS, morphine; RIM, rimonabant; ULD, ultra-low dose.
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dorsal spinal cord (Fig. 3a and b). Data collected from mul-
tiple trials are represented in the figure, and no data points
were excluded.
Similar to the effects of long-term morphine treatment on
microglial reactivity, morphine treatment also increased
expression of the astrocytic cytoskeletal protein GFAP.
However, this was only evident in the deep dorsal horn
(Fig. 3c and d, see Table 2 for statistics). Post-hoc analysis
revealed that vehicle-treated animals that received long-term
treatment with morphine had significantly higher labeling in
the deep dorsal horn (Fig. 3c) than the saline-treated controls
(P<0.001). This effect was not blocked by atipamezole, as
there remained a significant difference between morphine-
treated and saline-treated groups. However, there was a
Table 1 Summary of statistical analysis of data presented in Fig. 1
Three-way
ANOVA Fig. 1a – time course F P value Summary
Time F(4,60)=27.63 <0.0001 ***
Morphine F(1,60)=565 <0.0001 ***
Atipamezole F(1,60)=1.824 0.1819 NS
Morphine× atipamezole F(1,60)=6.659 0.0123 *
Three-way
ANOVA Fig. 1a – day 1 F P value Summary
Time F(6,84)=46.34 <0.0001 ***
Morphine F(1,84)=2270 <0.0001 ***
Atipamezole F(1,84)=0.680 0.4119 NS
Morphine× atipamezole F(1,84)=4.774 0.0317 *
Three-way
ANOVA Fig. 1a – day 7 F P value Summary
Time F(6,84)=2.053 <0.0675 NS
Morphine F(1,84)=132.1 <0.0001 ***
Atipamezole F(1,84)=15.34 0.0002 ***
Morphine× atipamezole F(1,84)=19.09 <0.0001 ***
Two-way
ANOVA
Fig. 1b – time
course F P value Summary
Time F(5,30)=11.67 <0.0001 ***
Treatment F(1,6)=8.615 0.0261 *
Interaction F(5,30)=2.776 0.0355 *
Two-way
ANOVA Fig. 1b – day 1 F P value Summary
Time F(6,36)=104.7 <0.0001 ***
Treatment F(1,6)=2.982 0.2488 NS
Interaction F(6,36)=5.532 0.0004 ***
Two-way
ANOVA Fig. 1b – day 7 F P value Summary
Time F(6,60)=11.22 <0.0001 ***
Treatment F(1,10)=8.715 0.0145 *
Interaction F(6,60)=5.324 0.0002 ***
Two-way
ANOVA
Fig. 1c –time
course F P value Summary
Time F(5,70)=23.47 <0.0001 ***
Treatment F(1,14)=4.005 0.0637 NS
Interaction F(5,70)=1.914 0.103 NS
Two-way
ANOVA Fig. 1c – day 1 F P value Summary
Time F(5,110)=5.93 <0.0001 ***
Treatment F(1,22)=0.005 0.9458 NS
Interaction F(5,110)=0.268 0.9297 NS
Two-way
ANOVA Fig. 1c – day 7 F P value Summary
Time F(6,84)=4.23 0.0009 ***
Treatment F(1,14)=0.098 0.7589 NS
Interaction F(6,84)=0.731 0.6256 NS
ANOVA, analysis of variance.
Significance is denoted as *P<0.05 and ***P<0.001.
Fig. 2
Representative micrographs demonstrating microglia (CD11b, left column
in red) and astrocytes (GFAP, right column in green) by fluorescent
immunohistochemistry in the superficial dorsal horn of rats treated chronically
for 7 days with saline vehicle, morphine (5mg/kg), morphine+ULD Ati
(17 ng/kg), or ULD Ati alone. ×63 magnification under oil immersion.
Ati, atipamezole; GFAP, glial fibrillary acidic protein; ULD, ultra-low dose.
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significant decrease in morphine-induced GFAP expression
between vehicle and atipamezole treatment (P<0.001).
To assess changes in the size of individual astrocytes,
three-dimensional models were quantified within the
deep and superficial dorsal horn of morphine+ vehicle-
treated and morphine+ atipamezole-treated groups.
Representative cells are shown as wireframe models
drawn to scale to allow for visual comparison (Fig. 4a–d).
Quantification of reconstructed GFAP-labeled stacks
showed that coadministration of ULD atipamezole sig-
nificantly decreased astrocyte cell volume in both the
deep (U= 240, P< 0.001) and superficial (U= 78,
P< 0.001) dorsal horn (Fig. 4e) compared with animals
receiving morphine and vehicle.
Similar to the aforementioned atipamezole experiment, in the
ULD RIM experiment, morphine significantly increased
CD11b expression in vehicle-treated animals in the superficial
(U=1, P<0.001) and deep (U=39, P<0.001) dorsal spinal
cord compared with saline-treated animals (Figs 5 and 6). In
contrast, animals coadministered ULD RIM+morphine
showed significantly lower levels of CD11b immunoreactivity
compared with the morphine+ vehicle group for both the
deep (U= 32, P< 0.001) and superficial (U= 4, P< 0.001)
dorsal spinal cord. Moreover, no significant difference was
noted in CD11b immunoreactivity of saline+ vehicle and
ULD RIM+morphine groups in either the deep (U= 112,
P=NS) or superficial (U= 121, P=NS) spinal cord. For
the RIM experiment, we also determined the effects of
treatment on another marker of microglial reactivity
(CD68). Similar to the effects of morphine on CD11b,
in the vehicle-treated groups, morphine significantly
increased CD68 expression in the deep (U= 30, P< 0.001)
and superficial (U= 43, P< 0.001) spinal cord compared
with saline treatment (Fig. 6). The concomitant adminis-
tration of RIM with morphine significantly blocked the
morphine-induced increase in CD68 in the spinal cord, as
there was no significant difference between the
RIM+morphine-treated and saline-vehicle-treated groups
and a significant difference between the morphine+
vehicle and RIM+morphine groups (Fig. 6).
In vehicle-treated animals, morphine significantly increased
GFAP expression in the deep (U=29, P<0.001) but not
superficial (U=88, P=NS) dorsal spinal cord (Fig. 7).
Coadministration of ULD RIM with morphine significantly
decreased GFAP immunoreactivity compared with the
Fig. 3
Coadministration of ULD atipamezole reduces chronic morphine-induced spinal gliosis in the deep and superficial dorsal horn of the spinal cord.
Graphs show mean pixel intensity of CD11b (a, b) and GFAP (c, d) labeling in collapsed stacks of the deep (a, c) and superficial (b, d) dorsal horn of
the L4–L5 spinal cord following 7 days of injections with saline, morphine alone (5 mg/kg), morphine+ULD atipamezole (17 ng/kg), or ULD
atipamezole alone. Three to six images were captured per region per animal from at least three animals per group. For the CD11b study, data were
pooled from three separate trials, and all collected data from those trials are shown, giving a total of 12–46 images per group for the CD11b study.
For the GFAP study, 10–12 collapsed stacks were quantified per group. Bars represent mean ±SEM. *P<0.05, **P<0.01, ***P<0.001,
****P<0.0001. a.u., arbitrary units; GFAP, glial fibrillary acidic protein; ULD, ultra-low dose.
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morphine-treated and vehicle-treated group (U= 47,
P< 0.01). No significant difference was observed between
the MS+RIM and vehicle-saline group (U= 118, P=NS).
Astrocyte cell volumes from the ULD RIM experiment
were quantified from three-dimensional reconstructions
of GFAP-labeled stacks (Fig. 8). An increase in astrocyte
hypertrophy was observed in the morphine group, com-
pared with vehicle, in both the superficial (U= 667,
P< 0.001) and deep (U= 628, P< 0.001) dorsal horn. In
the ULD RIM-treated groups, RIM+morphine was not
significantly different from the saline-vehicle treatment
group (superficial: U= 1079, P=NS) but was sig-
nificantly different from the morphine+ vehicle group
(deep: U= 623, P< 0.001, superficial: U= 745, P< 0.01),
demonstrating that RIM treatment significantly blocked
morphine-induced astrogliosis.
Discussion
The main objective of this study was to determine
whether previous reports of intrathecal administration of
ULD α2-AR antagonists attenuating opioid tolerance
could be replicated using a more clinical translational
dose regimen (systemic administration). A secondary goal
was to test the hypothesis that these paradoxical ULD
effects are common to another class of GPCR involved in
pain modulation, the CB1 receptor. Finally, we examined
whether observed behavioral changes correlated with
temporal changes in spinal gliosis induced by long-term
morphine treatment. Although both α2-AR antagonists,
atipamezole and efaroxan, attenuated morphine analgesic
tolerance, the CB1-antagonist RIM did not. In contrast,
both atipamezole and RIM attenuated the development
of long-term morphine-induced spinal gliosis. These data
suggest that the ULD effects are not ubiquitous among
GPCRs involved in modulation of nociception, and that
the mechanism of action may be distinct, given both
adrenergic and CB receptor antagonists prevented
opioid-induced spinal gliosis, but not the development of
analgesic tolerance.
These results are consistent with previous studies
demonstrating that intrathecal administration of α2-AR
antagonists attenuated the development of morphine
analgesic tolerance in both short-term and long-term
opioid tolerance models (Milne et al., 2008, 2013).
It seems likely, therefore, that α2-AR antagonists are
exerting effects in the present study, at least partially,
through an action within the spinal cord. Lilius et al.
Table 2 Summary of statistical analysis of data presented in Fig. 3
Two-way ANOVA Fig. 3a F P value Summary
Morphine F(1,124)=20.14 <0.0001 ***
Atipamezole F(1,124)=13.3 0.0004 ***
Interaction F(1,124)=0.357 0.5511 NS
Two-way ANOVA Fig. 3b F P value Summary
Morphine F(1,113)=15.6 0.0001 ***
Atipamezole F(1,113)=13.12 0.004 ***
Interaction F(1,113)=0.7235 0.3968 NS
Two-way ANOVA Fig. 3c F P value Summary
Morphine F(1,39)=0.1529 0.6980 NS
Atipamezole F(1,39)=7.647 0.0086 **
Interaction F(1,39)=36.38 <0.0001 ***
Two-way ANOVA Fig. 3d F P value Summary
Morphine F(1,43)=0.092 0.7633 NS
Atipamezole F(1,43)=70.03 <0.0001 ***
Interaction F(1,43)=0.0918 0.7633 NS
ANOVA, analysis of variance.
Significance is denoted as **P<0.01 and ***P<0.001.
Fig. 4
Coadministration of ULD atipamezole reduces long-term morphine-
induced astrocyte hypertrophy in the deep and superficial dorsal horn of
the lumbar spinal cord. The figure shows representative three-
dimensional reconstructions of astrocytes in the superficial (a, b) and
deep (c, d) dorsal horn of the spinal cord in animals treated over long
term with morphine (5 mg/kg) or morphine plus ULD atipamezole
(17 ng/kg) daily for 7 days. (e) Quantification of astrocyte cell volume.
Wireframes of the cells are represented to scale. Gray box dimensions
are 250×250 pixels. The three largest cells were quantified in each
area of each stack, with four stacks per animal from three animals per
group; total n=36/group. Bars represent mean±SEM. ***P<0.001.
Ati, atipamezole; a.u., arbitrary units; GFAP, glial fibrillary acidic protein;
ULD, ultra-low dose.
248 Behavioural Pharmacology 2018, Vol 29 No 2&3
Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
(2012) also reported that spinal administration of ULD
atipamezole attenuated the development of morphine
tolerance, but their finding that systemic administration
had no effect on this measure contradicts our current
results. This discrepancy can be explained by methodological
differences between the two studies: subcutaneous doses of
atipamezole in the study of Lilius et al. (2012) were several-
fold higher than ours, and their dosing paradigm to induce
morphine tolerance was more intense. Specifically, we used
daily injection of 5mg/kg morphine for 7 days, whereas Lilius
Fig. 5
Representative micrographs showing intensity of CD11b labeling of microglia within the deep (left column) and superficial lumbar dorsal horn in
animals chronically treated for 7 days with vehicle (top), MS plus ultra-low-dose CB1-receptor antagonist RIM (5 ng/kg), or MS alone (5 mg/kg).
×63 magnification under oil immersion. MS, morphine; RIM, rimonabant.
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et al. (2012) administered morphine twice daily for 4 days in
an escalating dosage paradigm starting at 10mg/kg on day 1
and rising to 30mg/kg on day 4. We also treated animals
chronically with the ULD α2-AR antagonists daily with or
without morphine; Lilius et al. (2012) administered atipame-
zole as a single injection in naive or morphine-tolerant animals
at the end of the dosing paradigm.
Two α2-AR antagonists were used in the present study.
The dose of atipamezole was selected from a pilot study
that identified an optimal dose for eliciting behavioral
responses. Efaroxan has a similar molecular weight to
atipamezole and was therefore administered at the same
dose. In competitive binding studies using RX821002
[a selective antagonist at α2-ARs that does not bind to
imidazoline receptors (Clarke andHarris, 2002)], atipamezole
was shown to have the highest binding affinity for α2-ARs in
the rat cortex (Ki=0.2 nmol/l) compared with other selective
ligands, and several-fold higher than efaroxan (Renouard
et al., 1994). Different potencies may explain some variations
in behavioral responses to the two drugs. Because more
robust effects were observed with atipamezole compared
with efaroxan, cellular effects of atipamezole were assessed
in the immunohistochemical studies.
Fig. 6
Quantification of mean pixel intensity of CD11b, CD68, and GFAP superficial is on the left and the deep is on the right. Morphine treatment
significantly increased fluorescence intensity of microglial (CD11b and CD68) in both deep and superficial dorsal spinal cord. Morphine treatment
also increased GFAP fluorescence intensity in the deep but not superficial dorsal horn. Animals cotreated with ultra-low-dose RIM showed an
attenuation of morphine-induced spinal gliosis in both areas commonly associated with the development of analgesic tolerance. Five to six sections
were imaged per animal per area, with at least three animals from each group, giving a total n=16/group. Bars represent mean ±SEM. **P<0.01,
***P<0.001. GFAP, glial fibrillary acidic protein; MS, morphine; RIM, rimonabant.
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Although the mechanism is currently unknown, ULD
α2-AR antagonists may be attenuating the development of
opioid tolerance by modulating neuronal–glial interactions.
Long-termmorphine administration (Hutchinson et al., 2007)
causes activation of microglia and astrocytes in the peripheral
and central nervous system, leading to the enhanced pro-
duction of proinflammatory cytokines and other inflamma-
tory mediators that can also contribute to the development
Fig. 7
Representative micrographs showing intensity of GFAP labeling of astrocytes within the deep (left column) and superficial (right column) lumbar
dorsal horn in animals chronically treated for 7 days with vehicle (top), MS plus ultra-low-dose CB1-receptor antagonist RIM (5 ng/kg), or morphine
alone (5 mg/kg). ×63 magnification under oil immersion. GFAP, glial fibrillary acidic protein; MS, morphine; RIM, rimonabant.
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of opioid analgesic tolerance (Raghavendra et al., 2002).
Previously, we reported that administration of a ULD opioid
antagonist, naltrexone, inhibits long-term morphine-induced
glial activation (Mattioli et al., 2010). Here, we extend the
findings to another system, reporting that long-term coad-
ministration of ULD atipamezole with morphine decreased
microglial reactivity and astrogliosis (inferred by CD11b and
GFAP immunolabeling, respectively) compared with ani-
mals treated with morphine alone. The change in morphine-
induced gliosis is small but significant, and it should not be
expected that drug administration would have dramatic
effects on glia cell size, because cell size is measured by
changes in cytoskeletal proteins and even the effects of
morphine are not more than a 25% increase in glial proteins.
The magnitude of the responses observed here is con-
sistent with past literature studies assessing ULD opioid
antagonists on morphine-induced gliosis. It is unknown if
these ULD antagonists are acting directly or indirectly
on α2-ARs on the glial cells to alter the development of
tolerance. Studies using RT-PCR and radioligand binding,
mRNA expression, and protein expression have shown that
all α-ARs are represented in astrocytes (Aoki, 1992; Porter
and McCarthy, 1997; Chen and Hertz, 1999; Hertz et al.,
2004; Hutchinson et al., 2011), therefore the potential of
these effects being direct is plausible.
Given the extent of cross-modulation between opioid
and CB systems and previous evidence that ULD opioid
antagonists modulate tolerance to a CB1-receptor agonist
(Paquette and Olmstead, 2005; Paquette et al., 2007), it
was surprising that we did not observe an effect of a ULD
CB1-receptor antagonist on morphine-induced tolerance.
At the same time, this supports the contention that cross-
talk between opioid and CB systems is asymmetrical
(Valverde et al., 2004). Although only one dose of the
CB1-receptor antagonist is shown in this study, two other
doses were assessed (1 and 50 ng/kg). None of the three
doses of RIM was able to modulate the development of
opioid tolerance, despite the 5 ng/kg dose being able to
attenuate astrocyte and microglial activation in the spinal
dorsal horn associated with tolerance development. The
expression of both CD11b and GFAP was reduced with
coadministration of ULD RIM with morphine, and three-
dimensional reconstructions of astrocytes showed that the
morphine-induced increase in cell size associated with
the phenotypic shift to a proinflammatory state was pre-
vented. The only region where a difference was not
observed was in the GFAP labeling in the superficial
dorsal horn. In this region, morphine did not cause a sig-
nificant upregulation in GFAP expression; thus, despite the
same general trend in all immunohistochemical graphs, any
effect of coadministration of ULD RIM might have been
masked. This fits with the attenuation of astrocyte hyper-
trophy in the same region in the three-dimensional recon-
structions. The expression of CD68, a marker of reactive
microglia, was also attenuated by coadministration of ULD
RIM. CD68 is predominately expressed on ‘activated’
microglia following the proinflammatory phenotypic shift
and not on quiescent microglia (Bachstetter et al., 2013;
Kaser-Eichberger et al., 2016).
Although there is a temporal correlation between spinal
glial activation and loss of opioid analgesia, attenuation of
gliosis by ULD antagonists alone does not appear to be
sufficient to prevent tolerance development. Thus, we
identify a dissociation between markers of neuroin-
flammation and gliosis with interventions that were pre-
viously reported to attenuate the development of
analgesic tolerance. Although the paradoxical effects of
ULD GPCR antagonists are more ubiquitous than once
believed, the exact mechanisms of action may be distinct,
depending on the class of receptor, its localization, and
what changes in expression or function are induced by
the model. Alternate mechanisms that could explain the
Fig. 8
Long-term coadministration of ultra-low-dose RIM attenuates chronic morphine-induced increases in astrocyte cell size associated with a shift to a
proinflammatory state that is believed to contribute to tolerance development. Glial fibrillary acidic protein-labeled stacks were reconstructed in three-
dimensions using ImagePro software and their size was quantified. Attenuation of spinal astrogliosis was observed in both the superficial (a) and deep
(b) dorsal horn. Five to six stacks were reconstructed per animal per area, with at least three animals from each group, giving a total n=16/group.
Bars represent mean±SEM. **P<0.01, ***P<0.001. GFAP, glial fibrillary acidic protein; MS, morphine; RIM, rimonabant.
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ability of the α2-AR antagonists to attenuate opioid
tolerance include changes in G-protein coupling and
signaling, which have been investigated for ULD opioid
antagonists (Chakrabarti et al., 2005; Wang et al., 2005,
Wang and Burns, 2006). It is unknown if a similar cou-
pling shift occurs with ULD α2-adrenergic antagonists,
and mechanistically, data interpretation become much
more complicated when investigating cross-modulation
of two different GPCR systems. In addition, a better
understanding of the functional interaction between
classes of GPCRs, including the possibility of hetero-
dimer formation, additivity, and synergy when multiple
receptors are activated simultaneously, and differential
changes in receptor expression in various cell types, will
lead to a better understanding of the paradoxical effects
of antagonists at ULD.
Ultimately, although the behavioral changes we observed
are small, we argue that this may indeed be clinically
relevant. In a clinical study where pain ratios assessed on
a visual analog scale score (100 mm scale) was 34 or lower,
a change of 13 was considered meaningful (see Bird and
Dickson, 2001), although with greater pain scores, larger
differences were needed to be considered clinically
relevant. These data show that a 13% change was needed
to be clinically meaningful, so although our effect is
small, it may still be clinically relevant. The magnitude of
the results observed here is comparable with previous
studies that investigated the use of ULD opioid antago-
nists such as naloxone and naltrexone in preventing the
loss of morphine potency over time in animal models.
The use of ULD opioid antagonists has actually trans-
lated well in terms of clinical effects in human patients
(Chindalore et al., 2005; Webster et al., 2006), and it
remains to be seen whether the effects of ULD α2-
adrenergic antagonists also translate from animal models
to humans.
The next step is to investigate the use of ULD α2-AR
antagonists in more clinically meaningful models,
including models of nerve injury and opioid reward.
Management of long-term pain and the overuse of
opioids are complex and controversial issues that place a
significant burden on patients and the health care system
as a whole. Use of ULD α2-AR antagonists could reduce
opioid tolerance and thus the total amount of opioids
needed to manage pain, diminishing adverse effects and
the dangers of escalating doses over time.
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